Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

NCT02231775 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions

DRUG: Dabrafenib
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Therapeutic Conventional Surgery
DRUG: Trametinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]